BR112022005787A2 - Proteínas de ligação a antígeno - Google Patents
Proteínas de ligação a antígenoInfo
- Publication number
- BR112022005787A2 BR112022005787A2 BR112022005787A BR112022005787A BR112022005787A2 BR 112022005787 A2 BR112022005787 A2 BR 112022005787A2 BR 112022005787 A BR112022005787 A BR 112022005787A BR 112022005787 A BR112022005787 A BR 112022005787A BR 112022005787 A2 BR112022005787 A2 BR 112022005787A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen binding
- binding proteins
- compositions
- treating
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906876P | 2019-09-27 | 2019-09-27 | |
| US202063057508P | 2020-07-28 | 2020-07-28 | |
| PCT/EP2020/076834 WO2021058711A2 (en) | 2019-09-27 | 2020-09-25 | Antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005787A2 true BR112022005787A2 (pt) | 2022-06-21 |
Family
ID=72840475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005787A BR112022005787A2 (pt) | 2019-09-27 | 2020-09-25 | Proteínas de ligação a antígeno |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11479607B2 (https=) |
| EP (1) | EP4034562B1 (https=) |
| JP (3) | JP7280387B2 (https=) |
| KR (1) | KR20220070011A (https=) |
| CN (2) | CN114729049B (https=) |
| AU (1) | AU2020355614B2 (https=) |
| BR (1) | BR112022005787A2 (https=) |
| CA (1) | CA3155173A1 (https=) |
| CO (1) | CO2022003053A2 (https=) |
| ES (1) | ES3053994T3 (https=) |
| IL (1) | IL291364A (https=) |
| MX (1) | MX2022003523A (https=) |
| MY (1) | MY207830A (https=) |
| PH (1) | PH12022550671A1 (https=) |
| TW (1) | TWI865617B (https=) |
| WO (1) | WO2021058711A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7280387B2 (ja) * | 2019-09-27 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質 |
| IL317083A (en) | 2022-06-17 | 2025-01-01 | Apogee Biologics Inc | Antibodies that bind interleukin 13 and methods of use |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| EP2000144A1 (en) | 2000-05-19 | 2008-12-10 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds |
| US7129219B2 (en) | 2000-08-04 | 2006-10-31 | Corixa Corporation | Immunoeffector compounds |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| CA2489004C (en) | 2002-06-13 | 2013-01-08 | Crucell Holland B.V. | Agonistic binding molecules to the human ox40 receptor |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2008073316A2 (en) | 2006-12-07 | 2008-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| EP2068925A4 (en) | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| SMT201700185T1 (it) | 2010-08-23 | 2017-05-08 | Univ Texas | Anticorpi anti-ox40 e metodi di uso degli stessi |
| ES2612914T3 (es) | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra Icos y usos de los mismos |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CA2845810C (en) | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| PL3036258T3 (pl) | 2013-08-22 | 2023-12-11 | The Council Of The Queensland Institute Of Medical Research | Modulowanie receptora dla leczenia raka i infekcji wirusowych |
| EP3036255A4 (en) | 2013-08-22 | 2017-03-22 | The Council Of The Queensland Institute Of Medical Research | Immunoreceptor modulation for treating cancer and viral infections |
| AU2015305754B2 (en) * | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| KR102528384B1 (ko) | 2017-01-06 | 2023-05-02 | 이뮤너티바이오, 인크. | 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포 |
| CN111655286A (zh) * | 2017-08-11 | 2020-09-11 | 布林克生物医学简易股份公司 | 作为免疫调节剂的cd96结合剂 |
| WO2019091449A1 (zh) | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | Cd96抗体、其抗原结合片段及医药用途 |
| TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| TW202122420A (zh) | 2019-08-30 | 2021-06-16 | 美商艾吉納斯公司 | 抗ｃｄ９６抗體及其使用方法 |
| JP7280387B2 (ja) * | 2019-09-27 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質 |
-
2020
- 2020-09-25 JP JP2021571490A patent/JP7280387B2/ja active Active
- 2020-09-25 MX MX2022003523A patent/MX2022003523A/es unknown
- 2020-09-25 PH PH1/2022/550671A patent/PH12022550671A1/en unknown
- 2020-09-25 AU AU2020355614A patent/AU2020355614B2/en not_active Ceased
- 2020-09-25 TW TW109133431A patent/TWI865617B/zh active
- 2020-09-25 BR BR112022005787A patent/BR112022005787A2/pt unknown
- 2020-09-25 CN CN202080080763.5A patent/CN114729049B/zh active Active
- 2020-09-25 EP EP20789858.6A patent/EP4034562B1/en active Active
- 2020-09-25 KR KR1020227014021A patent/KR20220070011A/ko not_active Withdrawn
- 2020-09-25 MY MYPI2022001598A patent/MY207830A/en unknown
- 2020-09-25 CN CN202411387665.2A patent/CN119431581A/zh active Pending
- 2020-09-25 WO PCT/EP2020/076834 patent/WO2021058711A2/en not_active Ceased
- 2020-09-25 ES ES20789858T patent/ES3053994T3/es active Active
- 2020-09-25 CA CA3155173A patent/CA3155173A1/en active Pending
-
2021
- 2021-11-19 US US17/530,849 patent/US11479607B2/en active Active
-
2022
- 2022-03-14 IL IL291364A patent/IL291364A/en unknown
- 2022-03-16 CO CONC2022/0003053A patent/CO2022003053A2/es unknown
- 2022-09-02 US US17/902,305 patent/US12528864B2/en active Active
-
2023
- 2023-05-10 JP JP2023078141A patent/JP7546723B2/ja active Active
-
2024
- 2024-08-20 JP JP2024139180A patent/JP2024167261A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI865617B (zh) | 2024-12-11 |
| CN114729049A (zh) | 2022-07-08 |
| EP4034562A2 (en) | 2022-08-03 |
| US11479607B2 (en) | 2022-10-25 |
| CN119431581A (zh) | 2025-02-14 |
| AU2020355614B2 (en) | 2024-12-05 |
| CN114729049B (zh) | 2024-10-25 |
| AU2020355614A1 (en) | 2022-04-14 |
| US12528864B2 (en) | 2026-01-20 |
| JP2022535034A (ja) | 2022-08-04 |
| ES3053994T3 (en) | 2026-01-28 |
| JP2024167261A (ja) | 2024-12-03 |
| CA3155173A1 (en) | 2021-04-01 |
| PH12022550671A1 (en) | 2023-05-29 |
| KR20220070011A (ko) | 2022-05-27 |
| CO2022003053A2 (es) | 2022-04-19 |
| MX2022003523A (es) | 2022-04-25 |
| US20230279106A1 (en) | 2023-09-07 |
| IL291364A (en) | 2022-05-01 |
| EP4034562C0 (en) | 2025-10-29 |
| US20220089728A1 (en) | 2022-03-24 |
| MY207830A (en) | 2025-03-21 |
| JP7546723B2 (ja) | 2024-09-06 |
| EP4034562B1 (en) | 2025-10-29 |
| WO2021058711A3 (en) | 2021-06-03 |
| TW202128755A (zh) | 2021-08-01 |
| JP2023103352A (ja) | 2023-07-26 |
| WO2021058711A2 (en) | 2021-04-01 |
| JP7280387B2 (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001879A (es) | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. | |
| ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| BR112022021884A2 (pt) | Proteínas que se ligam a nkg2d, cd16 e clec12a | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| BR112019023990A2 (pt) | Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas | |
| BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
| CO2018003973A2 (es) | Proteínas de unión a pd-1 y métodos para usarlas | |
| BR112017019300A2 (pt) | conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| BR112016029579A2 (pt) | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos | |
| BR112017013661A2 (pt) | conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| DOP2018000057A (es) | Composiciones biofarmacéuticas | |
| CO2021007882A2 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| MX2018013222A (es) | Anticuerpos de interferon beta y usos de los mismos. | |
| CU20170012A7 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 | |
| CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
| JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| BR112022005787A2 (pt) | Proteínas de ligação a antígeno | |
| BR112022001199A2 (pt) | Imunoterapia para poliomavírus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) |